Related Experiment Video
Updated: Sep 15, 2025

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
Pathological mechanisms and treatment progression of Alzheimer's disease
Jingjing Zhang1, Guoqing Kong2, Jinyue Yang1
1Department of Neurology, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, China.
Abstract:
Alzheimer's disease (AD) represents the most prevalent neurodegenerative disorder and leading cause of dementia worldwide, with its incidence rising dramatically in aging populations. This progressive disease is neuropathologically characterized by extracellular amyloid-β (Aβ) plaques, intracellular neurofibrillary tau tangles, and chronic neuroinflammation, leading to synaptic dysfunction and neuronal loss. Despite extensive research efforts, the complex and multifactorial nature of AD pathogenesis has prevented the development of truly disease-modifying therapies. Current therapeutic approaches, including recently approved anti-amyloid immunotherapies, demonstrate limited clinical efficacy and significant adverse effects, highlighting the need for alternative treatment strategies. This comprehensive review systematically evaluates recent advances in understanding AD pathophysiology, emphasizing the interplay between genetic risk factors (particularly APOE ε4), proteostasis imbalance, metabolic dysfunction, and neurovascular contributions. We critically analyze emerging diagnostic biomarkers, including novel neuroimaging techniques and cerebrospinal fluid/blood-based biomarkers, that enable earlier and more accurate detection. The review provides an in-depth assessment of both pharmacological interventions (such as tau-targeting therapies, anti-inflammatory agents, and neurotransmitter modulators) and non-pharmacological approaches (including lifestyle modifications and cognitive training). Special attention is given to personalized medicine strategies that account for disease heterogeneity and individual risk profiles. By synthesizing evidence from molecular studies, animal models, and clinical trials, we identify key challenges in therapeutic translation and propose future research directions. Our analysis underscores the importance of multimodal interventions targeting multiple pathological processes simultaneously, combined with early detection methods, to effectively combat this devastating disease. This review aims to provide researchers and clinicians with an updated framework for understanding AD pathogenesis and developing more effective treatment paradigms.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment
Parkinson's Disease: Overview
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Dementia
The progression of dementia is generally gradual....
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...

